AI could save the vision of newborns

AI technology could play a vital rule in the diagnosis and treatment of aggressive posterior retinopathy of prematurity (AP-ROP) in infants, according to new research published in Ophthalmology. AP-ROP, an especially severe form of ROP, is often not identified until it is too late to save the child’s vision.

The study involved a deep learning system recently fast-tracked for approval by the FDA and data from more than 947 newborns. The National Eye Institute (NEI), part of the National Institutes of Health, funded the research.

The AI-powered solution helped the authors develop a “quantifiable AP-ROP patient profile,” a key step in the treatment of this threatening, hard-to-predict disease. The authors found that infants with AR-ROP were more premature, for example, and had lighter birthweights. No infants born after 26 weeks developed AP-ROP, another crucial metric for the researchers to explore.

“AI has the potential to help us recognize babies with AP-ROP earlier,” J. Peter Campbell, MD, MPH, Oregon Health and Science University in Portland, said in a prepared statement. “But it also provides the foundation for quantitative metrics to help us better understand AP-ROP pathophysiology, which is key for improving how we manage it.”

“It's important to acknowledge that there is currently no gold standard for diagnosing AP-ROP,” Grace L. Shen, PhD, manager of the NEI’s retinal diseases program, said in the same statement. “But having objective, AI-based metrics for detecting AP-ROP is a step in the right direction for this highly vulnerable population of infants.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.